Adult Malignant Glioma Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: May 04, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.98 billion |
|
Revenue Forecast in 2031 |
US$ 4.68 billion |
|
CAGR |
9.57% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Therapy, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global adult malignant glioma therapeutics market was valued at US$ 1.98 billion in 2022 and is expected to register a revenue CAGR of 9.57% to reach US$ 4.68 billion by 2031.
Adult Malignant Glioma Therapeutics Market Fundamentals
Adult malignant gliomas are aggressive and lethal brain tumors arising from the brain's supportive tissue. They include glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma. The standard treatment for these tumors includes chemotherapy, radiation therapy, targeted therapy, immunotherapy, and gene therapy. The therapeutics market for adult malignant gliomas is quite significant due to the prevalence of these tumors and the limited treatment options available. The market for adult malignant glioma therapeutics is driven by several factors, including the increasing incidence of brain tumors in the aging population, ongoing research and development in the field of oncology, and the emergence of novel treatment modalities.
[356]
Adult Malignant Glioma Therapeutics Market Dynamics
Precision medicine involves tailoring treatment to the unique characteristics of each patient's tumor. Advances in genomic sequencing and molecular profiling have allowed for more precise diagnoses and targeted therapies for adult malignant gliomas. This approach aims to improve patient outcomes by providing personalized treatment plans based on the tumor's genetic makeup. Additionally, immunotherapy has emerged as a promising treatment approach for adult malignant gliomas. This approach aims to increase the effectiveness of treatment by targeting different aspects of the tumor simultaneously.
Moreover, there is ongoing research and development of new therapies for adult malignant gliomas. Clinical trials are a critical component of this research, and they allow for the evaluation of new treatment approaches and the identification of promising therapies. The blood-brain barrier presents a significant challenge in treating adult malignant gliomas, as it limits the delivery of drugs and other therapies to the brain. Novel delivery systems, such as convection-enhanced delivery (CED), are being studied to improve the delivery of therapies to the brain. Furthermore, AI and machine learning can potentially improve the diagnosis and treatment of adult malignant gliomas. AI can analyze large amounts of data to identify patterns and predict outcomes, which can help clinicians make more informed treatment decisions.
Adult malignant gliomas are highly heterogeneous tumors, meaning they can vary significantly in their genetic makeup and response to treatment. This heterogeneity can make identifying effective therapies that work for all patients challenging. The blood-brain barrier limits the delivery of drugs and other therapies to the brain, making it challenging to achieve effective treatment outcomes for adult malignant gliomas. Adult malignant gliomas can become resistant to chemotherapy, radiation therapy, and other treatments over time, limiting the effectiveness of these therapies in some patients. Despite ongoing research and development, limited treatment options are available for adult malignant gliomas, and the prognosis for these tumors remains poor. Many current treatment options for adult malignant gliomas can cause significant side effects, including fatigue, nausea, hair loss, and cognitive impairment. The cost of many current treatments for adult malignant gliomas can be prohibitive, limiting access to these therapies for some patients.
Adult Malignant Glioma Therapeutics Market Ecosystem
The global adult malignant glioma therapeutics market has been analyzed from the following perspectives: type, therapy, and region.
Adult Malignant Glioma Therapeutics Market by Type
[258]
Based on the types, the global adult malignant glioma therapeutics market is segmented into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others.
Glioblastoma multiforme is the most common and aggressive form of adult malignant glioma, accounting for most cases. As a result, glioblastoma multiforme dominates the global adult malignant glioma therapeutics market since it represents the largest patient population needing effective treatments. Furthermore, the prognosis for glioblastoma multiforme is poor, with a median survival time of around 15 months, and the disease is associated with significant morbidity and mortality. This creates a significant unmet need for effective treatments for glioblastoma multiforme patients, driving demand for innovative new therapies. In recent years, there have been several advances in glioblastoma multiforme treatment, including the development of targeted therapies, immunotherapies, and combination therapies, which have shown promising results in clinical trials. As a result, the glioblastoma multiforme segment of the adult malignant glioma therapeutics market is expected to grow as new therapies are developed and approved for use.
Anaplastic astrocytoma is a less aggressive form of adult malignant glioma than glioblastoma multiforme. However, it still represents a significant unmet medical need and is the second most common type of adult malignant glioma. As a result, the anaplastic astrocytoma segment holds the second-largest revenue share in the global adult malignant glioma therapeutics market. Anaplastic astrocytoma is a challenging disease to treat, and the prognosis is often poor, with a median survival time of around 2-3 years. There is a significant unmet need for effective treatments for anaplastic astrocytoma, which drives demand for new and innovative therapies. Like glioblastoma multiforme, several advances have been made in treating anaplastic astrocytoma, including the development of targeted therapies, immunotherapies, and combination therapies, which have shown promising results in clinical trials. These new therapies offer hope for improving patient outcomes and prolonging survival. In addition, the anaplastic astrocytoma segment of the adult malignant glioma therapeutics market is expected to grow as the population ages and the incidence of anaplastic astrocytoma increases. The global aging population is expected to drive the demand for effective treatments for anaplastic astrocytoma, which will further increase the revenue share of the anaplastic astrocytoma segment in the global adult malignant glioma therapeutics market.
Adult Malignant Glioma Therapeutics Market by Therapy
Based on the therapy, the global adult malignant glioma therapeutics market is segmented into chemotherapy, targeted therapy, and immunotherapy.
The chemotherapy segment accounts for the largest revenue share in the global market. Chemotherapy is the most common and widely used treatment modality for adult malignant glioma, including glioblastoma multiforme and anaplastic astrocytoma. Chemotherapy involves using drugs to kill cancer cells or prevent their growth and replication, and it can be administered orally or intravenously. Chemotherapy effectively slows tumor growth, reduces symptoms, and prolongs survival in some patients. In addition, several chemotherapy drugs have been approved for use in adult malignant glioma, including temozolomide, carmustine (BCNU), lomustine (CCNU), and procarbazine. These drugs are the backbone of many treatment regimens for adult malignant glioma, and they are often used in combination with other therapies, such as radiation therapy or immunotherapy. However, while chemotherapy is effective in some patients, it has significant limitations and side effects, such as nausea, fatigue, hair loss, and increased risk of infections. Moreover, many tumors can develop resistance to chemotherapy over time, limiting its effectiveness in some patients.
Similarly, the targeted therapy segment accounts for the second-largest revenue share in the global adult malignant glioma therapeutics market because it represents a promising and rapidly growing area of research and development for treating these tumors. Targeted therapies are drugs or other agents designed to selectively target specific molecules or pathways involved in the growth and spread of cancer cells while sparing normal cells. These therapies can potentially be more effective and less toxic than traditional chemotherapy, which targets both cancerous and normal cells. Several targeted therapies have been approved for use in adult malignant glioma, including bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and temozolomide, an alkylating agent that targets DNA. These drugs have shown promise in clinical trials and are often used with other therapies, such as chemotherapy or radiation therapy. In addition, there are several other targeted therapies in various stages of development for treating adult malignant glioma, including drugs that target epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and other molecular pathways involved in tumor growth and progression.
Adult Malignant Glioma Therapeutics Market by Region
Based on the region, the global adult malignant glioma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominates the global market with the largest revenue share. North America has a high incidence and prevalence of adult malignant glioma. This high disease burden creates a significant demand for effective treatments, which drives the market's growth. North America has a highly advanced healthcare infrastructure, well-developed healthcare systems, high-quality medical facilities, and a strong emphasis on research and development. This infrastructure allows for developing and rapidly adopting new and innovative therapies for adult malignant glioma. The regulatory environment in North America is highly supportive of developing and approving new drugs and therapies. The U.S. Food and Drug Administration (FDA) and Health Canada have well-established drug approval and post-market surveillance processes, ensuring that new therapies are safe and effective before they are approved for use. North America is home to several key players in the adult malignant glioma therapeutics market, including pharmaceutical and biotechnology companies, academic research institutions, and medical device manufacturers. These players drive innovation and development in the market and are well-positioned to bring new therapies to market. The availability of reimbursement for adult malignant glioma therapies in North America is generally high. This allows patients to access expensive treatments without a significant financial burden, which drives the market's growth.
The Asia Pacific region has seen a steady increase in the incidence and prevalence of adult malignant glioma in recent years, driven by factors such as aging populations and changing lifestyles. This has created a significant demand for effective treatments, driving the market's growth. The healthcare infrastructure in the Asia Pacific region has been rapidly improving, with increased investment in healthcare facilities, medical technologies, and healthcare personnel. This has increased access to healthcare services, including cancer treatment, further driving the market's growth. Governments and private organizations in the Asia Pacific region have invested heavily in cancer treatment research and development, including adult malignant glioma. This has led to the development of new and innovative therapies, further driving the market's growth. The Asia Pacific region has seen increasing adoption of targeted therapies for adult malignant glioma, which are often more effective and less toxic than traditional chemotherapy. This has increased demand for these therapies, driving the market's growth. The Asia Pacific region has a large and growing population, contributing to the increasing prevalence of adult malignant glioma. This large patient population has created a significant market opportunity for companies operating in the adult malignant glioma therapeutics market.
Adult Malignant Glioma Therapeutics Market Competitive Landscape
The prominent players operating in the global adult malignant glioma therapeutics market are:
The estimated market size of the global adult malignant glioma therapeutics market in 2031 is US$ 4.68 billion.
The revenue CAGR for the adult malignant glioma therapeutics market is 9.57% during the forecast period of 2023 to 2031
Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, and other notable players are some of the major key players in the adult malignant glioma therapeutics market.
The Asia Pacific region is projected to grow at high revenue CAGR in the global adult malignant glioma therapeutics market.
The glioblastoma multiforme segment dominates the global adult malignant glioma therapeutics market.
*Insights on financial performance are subject to the availability of information in the public domain
Recommended Reports